Novartis looks to offload even more of its eye products — report
Following its recent trend of offloading assets, Novartis is contacting potential buyers for some ophthalmology assets, Bloomberg reported Tuesday, citing people with knowledge of the matter.
Novartis is working with an advisor to offload front-of-eye treatments like its dry eye drug Xiidra, which was approved in 2016 in the US but failed to get approval in Europe. Nothing is set in stone — Novartis could still decide to keep the assets, Bloomberg reported, and not all are included in a potential sale. For example, Lucentis, a treatment for wet age-related macular degeneration, isn’t up for grabs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.